UY31710A - Anticuerpos monoclonales y su método de obtención - Google Patents

Anticuerpos monoclonales y su método de obtención

Info

Publication number
UY31710A
UY31710A UY0001031710A UY31710A UY31710A UY 31710 A UY31710 A UY 31710A UY 0001031710 A UY0001031710 A UY 0001031710A UY 31710 A UY31710 A UY 31710A UY 31710 A UY31710 A UY 31710A
Authority
UY
Uruguay
Prior art keywords
cells
antibody
disclosed
obtaining
monoclonal antibodies
Prior art date
Application number
UY0001031710A
Other languages
English (en)
Inventor
Lombardero Valladares Josefa
Rolando Perez Rodriguez
Jose Enrique Montero Casimiro
Melarkode Ramakrishnan
Nair Pradip
Sundarajaj David Rajkumar
Kedarnath Nanjund Sastry
Chatterji Monalisa
Adhikary Laxmi
Balasubramanian Hema
Original Assignee
Centro Inmunologia Molecular
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41064805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31710(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular, Biocon Ltd filed Critical Centro Inmunologia Molecular
Publication of UY31710A publication Critical patent/UY31710A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se divulgan un anticuerpo humanizado anti-CD6 de isotipo IgG1 (T1h) que se une al dominio 1(D1) del CD6 que es un receptor tipo SRCR (Scavenger Receptor CysteineRich) presente en la superficie de células del timo , monocitos, células T activadas y una variedad de otros tipos de células. Se divulgan los métodos para inhibir la proliferación de células T sin bloquear la interacción del CD6 y los ligandos naturales del CD6, como al ALCAM (del inglés: Activated Leukocyte Cell Adhesión MOLECULE), y el método de tratamiento de varias enfermedades utilizando el anticuerpo anti-CD6 que reconoce el D1 TIPO SCCR del CD6.
UY0001031710A 2008-03-14 2009-03-13 Anticuerpos monoclonales y su método de obtención UY31710A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN650CH2008 2008-03-14

Publications (1)

Publication Number Publication Date
UY31710A true UY31710A (es) 2009-11-10

Family

ID=41064805

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031710A UY31710A (es) 2008-03-14 2009-03-13 Anticuerpos monoclonales y su método de obtención

Country Status (26)

Country Link
US (6) US8524233B2 (es)
EP (2) EP2993186B1 (es)
JP (3) JP2011513479A (es)
KR (1) KR20100126811A (es)
CN (1) CN101970493A (es)
AR (1) AR072247A1 (es)
AU (1) AU2008352540B2 (es)
BR (1) BRPI0822447A2 (es)
CA (1) CA2716919C (es)
CL (1) CL2009000618A1 (es)
CO (1) CO6331445A2 (es)
DK (1) DK2993186T3 (es)
EA (1) EA201001467A1 (es)
ES (1) ES2759075T3 (es)
HK (1) HK1223941A1 (es)
IL (1) IL207917A0 (es)
MX (1) MX2010010085A (es)
MY (1) MY159517A (es)
NZ (1) NZ587632A (es)
PL (1) PL2993186T3 (es)
PT (1) PT2993186T (es)
TW (1) TWI485160B (es)
UA (1) UA104587C2 (es)
UY (1) UY31710A (es)
WO (1) WO2009113083A1 (es)
ZA (1) ZA201005843B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ578633A (en) * 2006-12-26 2012-03-30 Ct De Inmunolgia Molecular Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of b-chronic lymphocytic leukaemia
MX2010010085A (es) 2008-03-14 2011-03-29 Biocon Ltd Un anticuerpo monoclonal y el metodo para su uso.
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
BR112013007862A2 (pt) 2010-10-01 2019-09-24 Moderna Therapeutics Inc ácidos nucleicos manipulados e métodos de uso dos mesmos.
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR102062784B1 (ko) * 2013-07-23 2020-01-07 바이오콘 리미티드 단백질 내 푸코실화 수준을 제어하는 방법
EP3936148A1 (en) * 2013-07-23 2022-01-12 Biocon Limited Use of a cd6 binding partner and method based thereon
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN104497141B (zh) * 2014-12-31 2017-10-10 百泰生物药业有限公司 抗人cd6分子的治疗性抗体
CA2976219C (en) * 2015-02-12 2021-05-04 University Of Southern California Blockers of the growth hormone receptor in disease prevention and treatment
WO2017218750A1 (en) * 2016-06-15 2017-12-21 The Cleveland Clinic Foundation Novel anti-cd6 antibodies for treating t-cell mediated conditions
EP3528846A4 (en) * 2016-10-18 2020-06-03 Biocon Limited USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6
DK3529274T3 (da) 2016-10-21 2024-06-17 Biocon Ltd Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus
CN108178797B (zh) * 2017-12-29 2020-12-01 西南大学 一种抗家蚕BmSRC多克隆抗血清、制备方法及应用
JP7572041B2 (ja) 2018-02-27 2024-10-23 エクイリウム，インコーポレイテッド 重症喘息を処置するための組成物および方法
WO2020006568A1 (en) * 2018-06-29 2020-01-02 City Of Hope Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
CA3131299A1 (en) * 2019-02-26 2020-09-03 Equillium, Inc. Anti-cd6 antibody compositions and methods for treating lupus
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
JP2023530109A (ja) 2020-06-11 2023-07-13 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
IL311287A (en) 2021-09-08 2024-05-01 Ct Inmunologia Molecular Use of anti-CD6 monoclonal antibodies in the prevention of damage to cells and organs as a result of a hyper-inflammatory reaction

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US5998172A (en) 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
US5723437A (en) 1993-11-02 1998-03-03 Duke University CD6 ligand
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
SI9720021A (sl) 1996-03-20 1999-04-30 Hoechst Marion Roussel Triciklične spojine s specifično aktivnostjo za integrine, zlasti za integrine alfavbeta3, postopki za njihovo pripravo in intermediati teh postopkov, njihova aplikacija kot zdravila in farmacevtski sestavki, ki jih vsebujejo
EP0977991A4 (en) 1997-03-03 2004-12-15 Bristol Myers Squibb Co MONOCLONAL ANTIBODIES FOR HUMAN CD6
WO1998047531A2 (en) * 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
AU3633000A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
CN100358577C (zh) 1999-05-07 2008-01-02 杰南技术公司 抗体在制备治疗哺乳动物自身免疫病的试剂中的用途
CA2402596A1 (en) 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2001091793A1 (en) * 2000-05-26 2001-12-06 Smithkline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
ES2192128B1 (es) 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
EP1409018B1 (en) 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
US20040091490A1 (en) 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
EP1716181B1 (en) 2004-02-19 2009-12-16 Genentech, Inc. Cdr-repaired antibodies
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
DK2325207T3 (en) 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
EP1841456A2 (en) 2005-01-28 2007-10-10 Wyeth Stabilized liquid polypeptide formulations
EP1933873A4 (en) 2005-10-13 2009-12-02 Human Genome Sciences Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF PATIENTS WITH POSITIVE DISEASES FOR SELF-ANTIBODIES
BRPI0713421A2 (pt) 2006-06-14 2012-03-13 Imclone Systems Incorporated Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
US20110070225A1 (en) 2006-11-12 2011-03-24 Pierre Goldbach Beta antibody parenteral formulation
CN101199483B (zh) 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
NZ578633A (en) 2006-12-26 2012-03-30 Ct De Inmunolgia Molecular Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of b-chronic lymphocytic leukaemia
UY30838A1 (es) * 2006-12-26 2008-07-31 Centro Inmunologia Molecular Composicion farmacéutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide
AU2008204901A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-IL-13 antibody formulations and uses thereof
NZ579251A (en) 2007-02-28 2012-06-29 Schering Corp Engineered anti-il-23r antibodies
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
MX2009013886A (es) 2007-06-25 2010-01-27 Amgen Inc Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos.
WO2009037190A2 (en) 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
MX2010010085A (es) 2008-03-14 2011-03-29 Biocon Ltd Un anticuerpo monoclonal y el metodo para su uso.
EP2356146A1 (en) 2008-11-07 2011-08-17 Fabrus Llc Anti-dll4 antibodies and uses thereof
MX2012005863A (es) 2009-11-20 2013-01-18 Centro Inmunologia Molecular Formulaciones de anticuerpos.
CN102559636B (zh) 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
KR102062784B1 (ko) 2013-07-23 2020-01-07 바이오콘 리미티드 단백질 내 푸코실화 수준을 제어하는 방법
EP3936148A1 (en) 2013-07-23 2022-01-12 Biocon Limited Use of a cd6 binding partner and method based thereon
WO2017218750A1 (en) 2016-06-15 2017-12-21 The Cleveland Clinic Foundation Novel anti-cd6 antibodies for treating t-cell mediated conditions
WO2018024896A1 (en) 2016-08-05 2018-02-08 INSERM (Institut National de la Santé et de la Recherche Médicale) EX VIVO GENERATION OF γδ FOXP3+ REGULATORY T CELLS AND THERAPEUTIC USES THEREOF
EP3528846A4 (en) 2016-10-18 2020-06-03 Biocon Limited USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6
DK3529274T3 (da) 2016-10-21 2024-06-17 Biocon Ltd Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus
JP7572041B2 (ja) 2018-02-27 2024-10-23 エクイリウム，インコーポレイテッド 重症喘息を処置するための組成物および方法
CA3131299A1 (en) 2019-02-26 2020-09-03 Equillium, Inc. Anti-cd6 antibody compositions and methods for treating lupus
US20230151107A1 (en) 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
MX2023006595A (es) 2020-12-04 2023-08-11 Equillium Inc Metodos para dirigir selectivamente celulas con cd6alto y para disminuir la actividad de linfocitos tef.

Also Published As

Publication number Publication date
ZA201005843B (en) 2011-04-28
BRPI0822447A2 (pt) 2015-06-16
US8524233B2 (en) 2013-09-03
CL2009000618A1 (es) 2011-05-27
WO2009113083A1 (en) 2009-09-17
JP2014159425A (ja) 2014-09-04
AR072247A1 (es) 2010-08-18
CO6331445A2 (es) 2011-10-20
AU2008352540B2 (en) 2012-06-28
TWI485160B (zh) 2015-05-21
UA104587C2 (ru) 2014-02-25
US20170281808A1 (en) 2017-10-05
US20110002939A1 (en) 2011-01-06
IL207917A0 (en) 2010-12-30
EP2993186A1 (en) 2016-03-09
ES2759075T3 (es) 2020-05-07
PL2993186T3 (pl) 2020-02-28
NZ587632A (en) 2012-06-29
US20210122829A1 (en) 2021-04-29
US10000573B2 (en) 2018-06-19
CA2716919A1 (en) 2009-09-17
US9217037B2 (en) 2015-12-22
CA2716919C (en) 2015-01-20
CN101970493A (zh) 2011-02-09
MX2010010085A (es) 2011-03-29
JP5856209B2 (ja) 2016-02-09
PT2993186T (pt) 2019-11-29
MY159517A (en) 2017-01-13
DK2993186T3 (da) 2019-11-25
US10669346B2 (en) 2020-06-02
JP2011513479A (ja) 2011-04-28
KR20100126811A (ko) 2010-12-02
US11981743B2 (en) 2024-05-14
US20140031529A1 (en) 2014-01-30
EP2265644A4 (en) 2011-04-27
TW201000125A (en) 2010-01-01
EP2265644A1 (en) 2010-12-29
US20160168256A1 (en) 2016-06-16
EA201001467A1 (ru) 2011-06-30
US20180258179A1 (en) 2018-09-13
EP2993186B1 (en) 2019-09-04
US9670285B2 (en) 2017-06-06
HK1223941A1 (zh) 2017-08-11
AU2008352540A1 (en) 2009-09-17
JP2014065711A (ja) 2014-04-17

Similar Documents

Publication Publication Date Title
UY31710A (es) Anticuerpos monoclonales y su método de obtención
UY31707A1 (es) Composiciones herbicidas que comprenden piroxasulfona vii
CL2021001686A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
AR107902A2 (es) Anticuerpos anti-cd37
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
ECSP20020111A (es) Anticuerpos de b7-h4 y métodos para usarlos
PE20091404A1 (es) Composiciones y metodos para el tratamiento de tumores de origen hematopoyetico
ES2584956T3 (es) Anticuerpos anti-CD40 y usos de los mismos
EA201891992A1 (ru) Химерные рецепторы и способы их применения
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
RU2013113933A (ru) Антитело к cd38 и леналтдомид или бортезомиб для лечения множественной миеломы и nhl
EA202092417A1 (ru) Химерные рецепторы к dll3 и способы их применения
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
CO6351749A2 (es) Anticuerpos de interleucina-1 alfa y metodos de uso
AR065496A1 (es) Anticuerpos anti- il-23 r
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
EA201071137A1 (ru) Способы лечения
RS54113B1 (en) COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
AR072167A1 (es) Anticuerpos contra il-6 humano y sus usos
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
EA201790757A1 (ru) Связывающие антиген cd27l белки

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181017